Faculty of Medicine
Permanent URI for this communityhttps://repository.ukim.mk/handle/20.500.12188/14
Browse
13 results
Search Results
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, INEFFECTIVE ERYTHROPOIESIS IN PATIENT WITH BETA THALASSEMIA AND MYELODYSPLASTIC SYNDROME CASE REPORT(Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, 2024); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, DISTINCT SUBGROUP OF PATIENTS WITH UNMUTATED IGHV1-69 CHRONIC LYMPHOCYTIC LEUKEMIA AFFECTED WITH COVID19 INFECTION - SINGLE CENTER EXPERIENCE(Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, 2025); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, CLL-393 Outcomes of COVID-19 Infections in Patients With Hematological Malignancies in Republic of North Macedonia(Elsevier BV, 2022-10); ; Labachevska, Marija Popova - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Interplay between lymphocyte subpopulation, inflammatory cytokines and their correlation with oxidative stress parameters in COVID-19(PAGEPress Publications, 2023-01-12); ; ; ; <jats:p>Our objective was to investigate the inflammatory and oxidative stress markers in patients with moderate and severe form of COVID-19. In addition, we show the correlation between changes in lymphocyte subsets and markers of oxidative stress as a tool for patient classification. IL-6 and VEGF were analysed by utilizing a High Sensitivity Evidence Investigator™ Biochip Array technology. The total antioxidant capacity (PAT) and the free radical concentrations (d-ROM) were measured in serum utilizing analytical photometric system FRAS5. Peripheral blood was used to determine CD45 + mononuclear, B, T, and NK cells using a multi-parameter flow cytometric immunophenotypic test. Statistically significant differences in IL-6 and VEGF levels were observed between the two patient groups. Decreased values of the absolute number of lymphocytes and their CD4 + and CD8 + positive T cells, NK cells, and CD8 were obtained. In the moderate group, good correlations were found between IL-6 and VEGF and NK cells (r = 0.6973, p <0.05; for IL6 and r = 0.6498, p <0, for VEGF. 05). Cytokines were correlated with CD45+ (r = 0.5610, p <0.05; for IL-6 and r = 0.5462, p <0.05 for VEGF). The oxidative stress index can be used as a cheaper alternative and as a triage tool between severe and moderate illnesses, after showing good correlation with more expensive patient classification analysis.</jats:p> - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021)(Macedonian Academy of Sciences and Arts/Sciendo, 2021-04-23); ; Abstract The outbreak of the COVID-19 pandemic has generated the largest global health crisis of the 21st century, evolving into accelerating socioeconomic disruption. In spite of all rapidly and widely emerging scientific data on epidemiology, diagnosis, prevention and treatment of the COVID-19 disease, severe acute respiratory coronavirus 2 (SARS-CoV-2) is continuing to propagate in lack of definitive and specific therapeutic agents. Current therapeutic strategies are mainly focused on viral inhibition by antiviral drugs and hampering the exuberant immune response of the host by immunomodulatory drugs. In this review, we have studied the reports of the largest clinical trials intended to COVID-19 treatment published during the first year of the pandemics. In general, these results concentrate on seven therapeutic options: remdesivir, chloroguine/hydroxychloroquine, lopinavir-ritonavir combination, corticosteroids, tocilizumab, convalescent plasma and monoclonal antibodies. In line with the reviewed data, as of January 2021, most of the evidence support the use of remdesivir in hospitalized patients with moderate and severe forms of the disease and provide reliable data on the substantial beneficial effect of corticosteroids in patients requiring supplemental oxygen. Moreover, preliminary RECOVERY trial results have demonstrated the efficacy of tociluzumab in the treatment of critically ill patients. The reports presenting the outcomes of the other immune-based therapies under investigation are enthusiastically awaited. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Hematologic Autoimmune Manifestation Secondary to Coronavirus Disease 19 Infection – A Single-Center Experience(Scientific Foundation SPIROSKI, 2021-09-11); ; ; <jats:p>Introduction: Since December 2019, multiple human cases of novel coronavirus infection were reported, representing with upper respiratory symptoms (influenza-like presentation). The virus was named the Severe acute respiratory system coronavirus 2 (SARS-COV-2). Studies have reported cases of patients with COVID-19 infection, including development of several autoimmune events that suggests that infection with SARS CoV-2 may be associated with initiation of autoimmune hematological autoimmune disorders. Aim: Review the hematological autoimmune phenomenon after infection with SARS-COV-2 in order to assist into the pathogenic mechanisms, clinical manifestations and treatment of this group of patients. Materials and methods: This is a retrospective study that includes 21 patients with autoimmune diseases like secondary immune thrombocytopenia (ITP), autoimmune hemolytic anemia( AIHA) and thrombotic thrombocytopenic purpura (TTP) that have emerged after COVID-19 infection. The patients were diagnosed and treated at the University Clinic of Hematology for a period of time from January 2020 to April 2021. Results: The most common hematologic autoimmune disorder was ITP in 13 cases (62%) followed by AIHA in 5 cases (24%) and TTP in 3 individuals (14%). The mean time of onset of the hematologic auto-immune presentations was 18,4 ± 10,3 days. The therapy of this conditions in patients with COVID-19 infection requires an individualized approach to achieve a precise balance between the risk of severe bleeding and of thromboembolic events. Conclusion: Causal relationship between COVID-19 infection and these autoimmune events still requires further studies. We should all have in mind the risk of development of hematologic autoimmune disorders in infected patients. </jats:p> - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Poster: MM-326: Visceral Leishmaniasis Mimicking Multiple Myeloma(Elsevier BV, 2021-09); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, AML-327: Plasmacytoid Dendritic Cell Proliferation Associated with Acute Myeloid Leukemia: A Case Report(Elsevier BV, 2021-09); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Poster: HL-325: A Case Report of Classic Hodgkin Lymphoma with Unusually Abundant Tumor Cell Expression of B-Cell Markers: A Diagnostic Dilemma and Treatment Challenge(Elsevier BV, 2021-09); ; Trajkova, Sanja